Gen­mab ends de­vel­op­ment of Phase 3 lung can­cer as­set that BioN­Tech ditched ear­li­er
Gen­mab is end­ing clin­i­cal de­vel­op­ment of aca­sun­limab, a bis­pe­cif­ic an­ti­body that the biotech had worked on with BioN­Tech un­til that part­ner
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
CMS un­veils Medicare cov­er­age mod­el for weight loss drugs
Bio­haven’s ion chan­nel drug fails again, this time in ma­jor de­pres­sive dis­or­der
J&J ax­es eczema drug from .25B ac­qui­si­tion
Fed­er­al judge blocks 340B drug pric­ing pi­lot ahead of Jan. 1 ef­fec­tive date
Gene edit­ing's search for a 'holy grail' has led to an ex­plo­sion of tools, but few cures
Ul­tragenyx, Mereo crash on late-stage bone dis­ease fail­ure
Nido Bio to wind down af­ter un­der­whelm­ing Phase 2 da­ta
ASK Pharm makes Chi­na rights deal; Uni­cy­cive re­sub­mits kid­ney drug af­ter CRL
The End­points win­ners and losers list: Who was up and who was down in 2025
Bioscience & Technology Business Center